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ABSTRACT  
Objective. To investigate the role in atherosclerosis of the tumor suppressor gene ARF 
(human p14ARF, mouse p19Arf) encoded by the CDKN2A gene. 
Background. Atherosclerosis is characterized by excessive proliferation and apoptosis, two 
cellular processes regulated by CDKN2A. Whilst recent genome-wide association studies 
have linked atherosclerotic diseases to a genomic region in human chromosome 9p21 near 
the CDKN2A locus, the mechanisms underlying this gene-disease association remain 
undefined and no causal link has been established between CDKN2A and atherosclerosis.  
Methods. Atherosclerosis-prone apolipoprotein E (apoE)-null and doubly-deficient apoE-
p19Arf mice were fed an atherogenic diet and sacrificed to quantify atherosclerosis burden in 
whole-mounted aortas and in aortic cross-sections. Proliferation and apoptosis were 
investigated in atherosclerotic lesions and in primary cultures of macrophages and vascular 
smooth muscle cells obtained from both groups of mice.  
Results. Genetic disruption of p19Arf in apoE-null mice augments aortic atherosclerosis 
without affecting body weight, plasma lipoproteins and plaque’s proliferative activity. Notably, 
p19Arf deficiency significantly attenuates apoptosis both in atherosclerotic lesions and in 
cultured macrophages and vascular smooth muscle cells, two major cellular constituents of 
atheromatous plaques.  
Conclusions. Our findings establish a direct link between p19Arf, plaque apoptosis and 
atherosclerosis, and suggest that human genetic variants associated to diminished CDKN2A 
expression may accelerate atherosclerosis by limiting plaque apoptosis. 
Key words: ARF, CDKN2A, atherosclerosis, apoptosis, macrophage, vascular smooth 
muscle cell  
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Abbreviations 
apoE: apolipoprotein E 
BMDM: bone marrow derived macrophage 
BrdU: bromodeoxyuridine 
GSNO: S-nitrosoglutathione 
HDL-C: HDL-cholesterol 
LDL: low-density lipoprotein 
SNP: single nucleotide polymorphism 
UV: ultraviolet light 
VSMC: vascular smooth muscle cell 
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INTRODUCTION 
Atherosclerosis and coronary artery disease are the major cause of mortality in Western 
societies. Atheroma development is a chronic inflammatory process resulting from the 
interaction between modified lipoproteins, circulating leukocytes and elements of the arterial 
wall, including endothelial cells, monocyte-derived macrophages, T-cells, and vascular 
smooth muscle cells (VSMCs) (1-4). The disease in humans and experimental animals is 
characterized by excessive cell proliferation and apoptosis within the atheroma, two 
processes which affect mainly to macrophages and VSMCs (5-9). 
The tumor suppressors p15INK4b, p16INK4a, and ARF (p14ARF in humans, p19Arf in mice) 
constitute one of the main anti-oncogenic defenses of mammalian organisms (10,11). The 
CDKN2A gene encodes the non-homologous proteins p16INK4a and ARF, and the adjacent 
CDKN2B gene encodes p15INK4b. p16INK4a and p15INK4b cause growth arrest through the 
inhibition of CDK4 and CDK6 activity and the ensuing accumulation of the 
hypophosphorylated form of the retinoblastoma protein (12,13). ARF appears to play a more 
relevant role as a pro-apoptotic factor via inhibition of MDM2, an ubiquitin-ligase that 
destabilizes the tumor suppressor p53 (10,11). Furthermore, age-dependent expression of 
p16INK4a and ARF may limit the regenerative potential of stem cell pools in certain tissues (14-
17).  
By analyzing a small cohort that included 316 patients and 434 controls, Rodriguez et al. 
reported lack of association between the risk of suffering myocardial infarction and the single 
nucleotide polymorphisms (SNPs) rs3731238, rs3814960, rs3731249 located in the CDKN2A 
gene (18). However, recent independent genome-wide association studies that included  
thousands of controls and patients have identified a number of SNPs located in a region of 
chromosome 9p21 very close to the CDKN2A gene which are linked to high risk of 
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atherosclerosis and associated cardiovascular disease, including coronary artery disease, 
myocardial infarction, and ischemic stroke (19-25). Interestingly, Liu et al. recently reported 
reduced expression of the CDKN2A transcripts p16INK4a, p14ARF and the non-coding RNA 
named ANRIL (antisense noncoding RNA in the INK4 locus)  in purified peripheral blood T-
cells of individuals carrying in homozygosis the atherosclerosis risk G-allele of rs10757278 
(26). These studies suggest a molecular mechanism by which diminished expression of 
CDKN2A transcripts associated to genetic variants in this locus increases the risk of 
atherosclerosis. However, a causal link between reduced CDKN2A expression and 
atherosclerosis has not been established. Here we investigated the consequences of 
inactivating p19Arf on atheroma development in the widely-used apolipoprotein E-null (apoE-/-) 
mouse model of atherosclerosis.  
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METHODS 
 
Mice, diets and metabolic measurements. Care of animals was in accordance with 
institutional guidelines and regulations. Mice deficient for p19Arf (p19-/-) (27) were 
backcrossed for more than eight generations in a C57BL/6J background and then were 
crossed with apoE-/- mice (C57BL/6J, Charles River) to generate doubly-deficient apoE-/-
p19-/-  mice. Information for genotyping of mice is provided in the online supplement. After 
weaning, mice were maintained on a low-fat standard diet (2.8% fat; Panlab, Barcelona, 
Spain). At two months of age, male apoE-/- and apoE-/-p19-/- littermates were placed for 
different periods of time on an atherogenic diet (10.8% total fat, 0.75% cholesterol without 
sodium cholate, S4892-E010, Ssniff, Germany). 
Plasma lipid levels in mice fasted overnight were measured using enzymatic procedures 
(WAKO, St. Louis, USA). HDL-cholesterol (HDL-C) was determined after precipitation of the 
apolipoprotein B-containing lipoproteins with dextran-sulphate/MgCl2 (SIGMA, St. Louis, USA) 
as previously described (28).  
 
Quantification of atherosclerosis burden. Fat-fed mice were sacrificed and the aorta was 
removed after in situ perfusion with PBS followed by 4% paraformaldehyde/PBS. Fixation was 
continued overnight. An operator who was blinded to genotype quantified the extent of 
atherosclerosis by computer-assisted morphometric analysis (SigmaScan, Pro5) of both 
whole-mounted aorta stained with Oil Red O (Sigma, 0.2% Oil Red O in 80% MeOH) and 
hematoxylin/eosin-stained cross-sections of paraffin-embedded aortic root and ascending 
aorta as previously described (29).  
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Immunohistochemical analysis of atherosclerotic plaques. Immunohistopathological 
examination of atheromas performed by a researcher blinded to genotype included the 
quantification of the content of macrophages, VSMCs, and collagen (Masson’s trichrome 
stain). VSMCs were identified with mouse anti-smooth muscle α-actin (SMα-actin) monoclonal 
alkaline phosphatase-conjugated antibody (1/20 dilution, clone 1A4) and Fast Red substrate 
(both from Sigma). Macrophages were detected with a rat anti-Mac3 monoclonal antibody 
(1/200 dilution, clone M3/84, sc-19991, Santa Cruz Biotechnology), followed by biotin-
conjugated goat anti-rat secondary antibody (1/300 dilution, sc-2041, Santa Cruz 
Biotechnology), streptavidin-HRP (Ref. TS-060-HR, Lab vision Corporation, USA) and DAB 
substrate (BUF021A, AbD SEROTEC). Specimens were counterstained with hematoxylin.  
Cell proliferation in atheromatous lesions from the aortic valves and ascending aorta was 
estimated by immunostaining with a prediluted rabbit anti-Ki67 monoclonal antibody (Clone 
SP6; MD, Vector), followed by incubation with a biotinylated anti-rabbit secondary antibody 
(1/300 dilution, Ref. R0919, Vector), streptavidin-HRP and DAB substrate.  
Apoptosis in the aortic valve region was determined using the TUNEL method as 
recommended by the manufacturer (ApopTag Peroxidase In Situ Apoptosis Detection Kit, Ref. 
S7100, Millipore). Immunocomplexes were detected with DAB substrate and counterstained 
with hematoxylin.  
For double TUNEL-Mac3 and TUNEL-SMα-actin staining, TUNEL-stained slides were 
incubated with the anti-Mac3 or anti-SMα-actin antibodies, respectively (see above). The 
TUNEL-Mac3 stained specimens were incubated with biotin-conjugated goat anti-rat 
secondary antibody and streptavidin-alkaline phosphatase (1/50, Ref. 551008, BD 
Pharmingen). In both cases, immunocomplexes were detected with Fast Red substrate 
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(Sigma). Apoptotic macrophages and VSMCs were quantified as the percentage of Tunel+ 
cells that were also Mac3+ or SMα-actin+ cells, respectively. Images were captured with an 
Olympus CAMEDIA-C5060 wide zoom digital camera mounted on an Axiolab 
stereomicroscope (Zeiss). 
 
Primary cell cultures. Bone marrow-derived macrophages (BMDMs) were obtained from 
femoral bone marrow suspensions plated at 3x106 cells/mL and differentiated for 7 days in the 
presence of DMEM/10%FBS/10% macrophage-colony stimulating factor (29). VSMC cultures 
were prepared from thoracic aorta harvested from 3-5-month-old animals after two digestions 
in HBSS/Fungizone medium as previously described (29). Briefly, the aorta was first digested 
with type II collagenase (175U/mL, Worthington Biochemical Corp.) to remove the adventitia, 
and cell suspensions were obtained after a second digestion with type II collagenase 
(175mg/mL) (Worthington) and type I Elastase (0.5mg/mL) (Sigma) gave rise to. Cultures 
were maintained at 37 °C in a humidified 5% CO2 atmosphere. VSMCs were cultured in 20% 
FBS/DMEM/Fungizone and used until passage ten. The identity of the cells as VSMCs was 
confirmed by immunohistochemistry using anti-SM-actin antibody (see above).  
 
In vitro cell proliferation. For proliferation studies, asynchronously growing cultures of 
BMDMs were plated in glass coverslips and incubated with 50 µM bromodeoxyuridine (BrdU) 
for 18h. Cells were fixed for 30 min with 4% paraformaldehyde/PBS, permeabilized with 0.5% 
Triton X-100/2 M HCl, washed extensively with sodium borate buffer [pH 8.5] and incubated 
with a mouse monoclonal anti-BrdU antibody (1h, room temperature, 1/200, clone MoBu-1, 
11-286-c100, Exbio) followed by an Alexa Fluor 488-conjugated goat anti-mouse secondary 
antibody (1h, room temperature, 1/500, A11029, Invitrogen). Cell nuclei were stained with 
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Hoechst (1/500, 15 min, Sigma) for total cell count and coverslips were mounted with slow-
fade gold antifade reagent (S36936, Invitrogen) and analyzed by fluorescent microscopy. For 
VSMC FACS-based cell cycle analysis, cells were synchronized in G0/G1 by 72h serum-
deprivation (DMEM-0.1% FBS) and then restimulated with DMEM-20% FBS for different 
times. Cells were trypsinized, washed with PBS, collected by centrifugation (5 min, 600g), 
fixed with 80% ethanol (1h, -20ºC) and labeled with propidium iodide (50 μg/mL, 30min at 
room temperature containing 0.25 mg/mL RNAse A). Cells were analyzed using a BD 
FACSCantoTM Flow cytometer and DNA histograms were fitted into cell cycle distributions 
using the ModFit 3.0 software (Verity Software House). 
In vitro apoptosis. Cells were either irradiated with ultraviolet light (UV) (BMDM: 80J/m2, 
VSMC: 120J/m2) and cultured an additional 24h (BMDM) or 48h (VSMC), incubated with free-
cholesterol at 100 μg/mL (BMDM: 24h, VSMC: 48h), or incubated with the nitric oxide donor 
GSNO (2mM, Sigma) (BMDM: 24h, VSMC: 48h). For apoptosis analysis by flow cytometry, 
control and treated cells were collected by trypsinization at 37ºC, rinsed with PBS, collected at 
low speed (700g, 5 min) and fixed for propidium iodide staining as above or for cleaved 
caspase-3 staining as follows. Cells were fixed 10 min at 37ºC with 2-4% 
paraformaldehyde/PBS, permeabilized with prechilled 90% methanol (30 min on ice) and 
stained with a rabbit polyclonal anti-cleaved caspase 3 (Asp175) antibody (1/200, Cell 
Signalling), followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody 
(F(ab’)2 fragment, 1h at room temperature, 1/500, A-11070, Invitrogen). Apoptotic cells were 
identified as the sub-G0 peak subpopulation after propidium iodide staining or as cleaved 
caspase-3 (Asp175)-positive cells. 
Statistical analysis. Data are presented as mean±SEM. Differences among groups were 
evaluated by Student’s t-test, two-way ANOVA with Fisher’s post-hoc test (Statview, SAS 
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institute, Cary, USA) or nonparametric Mann Whitney U-test (GraphPad Prism Software, Inc.). 
Outliers identified by Grubb´s test were not considered for quantification. 
 
 
RESULTS 
Genetic disruption of p19Arf accelerates atherosclerosis in apoE-/- mice. To assess the 
role of p19Arf on atherosclerosis, two-month-old apoE-/- mice and apoE-/-p19-/- siblings were fed 
a high-fat cholesterol-rich diet for 9 weeks. As shown in Fig.1A, body weight increased in both 
groups of mice during the period of fat feeding, reaching statistically significant differences in 
apoE-/- mice at 4 and 9 weeks versus 0 and 1 week and in apoE-/-p19-/- mice at 4 weeks 
versus 0 and at 9 weeks versus 0, 1 and 4 weeks (see p values in Fig.1A). No differences 
were observed between apoE-/- and apoE-/-p19-/- mice at any time point analyzed. Likewise, 
circulating levels of total cholesterol and triacylglycerides increased significantly in both 
groups of fat-fed mice compared to their prediet values (Fig.1B), but no differences were seen 
when comparing apoE-/- and apoE-/-p19-/- mice. Thus, body weight and circulating lipids in 
control and fat-fed apoE-null mice remained unaffected by genetic disruption of p19Arf. We 
next quantified atherosclerosis burden by planimetric analysis of whole mounted oil Red-O-
stained aortic arch and thoracic aorta and by analyzing cross-sections through the aortic root 
and ascending aorta. Compared to apoE-/- counterparts, apoE-/-p19-/- mice exhibited a 
significant increase in atheroma size in the aortic arch (1.5-fold, p<0.012) (Fig.1C) and aortic 
root (1.7-fold increase, p<0.018) (Fig.1D), two highly atherogenic vascular beds in this animal 
model. In contrast, p19Arf inactivation did not affect plaque size in the less atherogenic 
thoracic aorta (Fig.1C) and ascending aorta (Fig.1D).  
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We also examined the consequences of inactivating p19Arf on plaque composition. 
Analysis of the aortic root and ascending aorta revealed no differences in lesional (neointimal) 
content of Mac3-immunoreactive macrophages, SMα-actin-immunoreactive VSMCs and 
collagen between apoE-/-p19-/- and apoE-/- mice (Fig.2). Likewise, lesion cellularity in the aortic 
root did not reveal statistically-significant differences between both groups (apoE-/-: 6.21±1.02 
cells/mm2, n=11; apoE-/-p19-/-: 6.07±1.13 cells/mm2, n=10).  
 
Effects of p19Arf inactivation on cell proliferation and apoptosis in atherosclerotic 
lesions and macrophage and VSMC cultures. We next sought to investigate the 
mechanisms underlying the atheroprotective action of p19Arf. Since a key event in lesion 
development is the uptake of modified low density lipoproteins (LDLs) by macrophages (1), 
we analyzed this process in cultures of peritoneal macrophages obtained from apoE-/- and 
apoE-/-p19-/-  mice, which exhibited similar uptake of acetylated-LDLs (data not shown). We 
also examined the effect of disrupting p19Arf on proliferation and apoptosis, two important 
cellular processes during atherosclerosis (5-9,30). Asynchronously growing cultures of BMDM 
obtained from apoE-/- and apoE-/-p19-/- mice exhibited similar proliferative activity measured as 
BrdU incorporation (Fig. 3A) and flow cytometric analysis (not shown). In contrast, apoE-/-p19-
/- VSMCs entered earlier into the S- and G2/M-phase of the cell cycle compared with apoE-/- 
controls, as determined by flow cytometric analysis of starvation-synchronized cultures that 
were restimulated with serum (Fig. 3B). These studies demonstrated significantly higher % of 
cells in G1/G0 in apoE-/- versus apoE-/-p19-/- VSMCs at all time points analyzed, and 
significantly higher % of cells in S (16 and 24h) and G2/M (8, 16 and 24h) in apoE-/-p19-/- 
versus apoE-/- cultures.  Moreover, differences in the %  of apoE-/- cells in G1/G0-, S- and 
G2/M-phases only reached statistical significance after 24h of serum restimulation compared 
to 0h (p<0.0001). However, in apoE-/-p19-/- VSMCs, differences in G1/G0-, S- and G2/M-
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phases reached statistical significance at 8, 16 and 24h after serum restimulation compared to 
0h (8h vs 0h and 16h vs. 0h: p<0.05; 24h vs. 0h: p<0.0001). Taken together, these findings 
suggest that serum-restimulated  apoE-/-p19-/- VSMCs reenter the cell cycle faster than apoE-/- 
cells. 
In spite of the increased proliferative capacity of cultured VSMC lacking p19Arf, cell 
proliferation was similar in aortic-root cross-sections from apoE-/- and apoE-/-p19-/- mice fed the 
atherogenic diet for 9 weeks (Fig. 3C), as estimated by the neointimal content of Ki67-positive 
cells. Likewise, quantification of neointimal Ki67-immunoreactive cells in the ascending aorta 
did not reveal statistically-significant differences between both groups (apoE-/-: 
52.9±5.6%Ki67-positive cells, n=11; apoE-/-p19-/-: 46.9±4.8%Ki67-positive cells, n=10, 
p>0.05). Neointimal cell proliferation was also undistinguishable in apoE-/- and apoE-/-p19-/- 
mice fed the atherogenic diet for 4 weeks, which exhibited incipient lesions (Fig.S1 in online 
Supplement). Interestingly, the mRNA level of the cytostatic gene p16INK4a was markedly 
increased in the aortic arch of apoE-/-p19-/- mice fed the atherogenic diet for 4 weeks (~17-fold 
increase vs. apoE-/-, p<0.05) and 9 weeks (~23-fold increase vs. apoE-/-, p<0.0005) (Fig.S2A 
in online Supplement). This compensatory mechanism does not occur in cultured VSMCs, 
since no statistically-significant differences in p16INK4a expression were detected when 
comparing cells of both genotypes (Fig.S2B). We also observed that expression of p15INK4b in 
both aortic tissue and cultured VSMCs is unaffected by disrupting p19Arf (Fig.S2). Thus, p19Arf 
ablation increases significantly the proliferative capacity of cultured VSMCs in vitro but does 
not affect neointimal cell proliferation at different lesional stages, possibly due to a 
compensatory upregulation of p16INK4a in aortic tissue. 
To assess the role of p19Arf in plaque’s apoptosis, aortic root cross-sections were 
examined using the TUNEL method. We found a significant reduction in the percentage of 
TUNEL-positive cells in atheromas from apoE-/-p19-/- compared to apoE-/- mice, both when 
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quantified as %TUNEL-positive cells and as absolute number of TUNEL-positive cells per 
mm2 of lesion (Fig.4A). We also carried out double staining experiments to identify apoptotic 
neointimal macrophages (TUNEL/Mac3) and VSMCs (TUNEL/SM α-actin). In both groups of 
mice, ~70% and <4% of apoptotic cells in atherosclerotic lesions were macrophages and 
VSMCs, respectively (Fig.4B, results expressed as % of cells doubly positive for TUNEL and 
Mac3 or SMα-actin relative to the total number of TUNEL-positive cells within the atheroma). 
To further investigate the role of p19Arf in the control of macrophage and VSMC 
apoptosis, we prepared primary cultures of BMDMs and VSMCs from apoE-/- and apoE-/-p19-/- 
mice and exposed them to several pro-apoptotic stimuli, including UV, the nitric oxide donor 
S-nitrosoglutathione (GSNO), and free-cholesterol. As shown in Fig.5A, p19Arf deficiency 
significantly reduced apoptosis in BMDMs treated with all three stimuli, as measured using 
two flow cytometry approaches (propidium iodide staining to identify sub-G0 cells and cleaved 
caspase-3 immunostaining). Similarly, p19Arf inactivation in apoE-/- VSMCs significantly limited 
apoptosis induced by UV and GSNO (Fig.5B). Free-cholesterol, which induced apoptosis in 
macrophages (Fig.5A and (31)), failed to provoke apoptotic cell death in apoE-/- and apoE-/-
p19-/- VSMCs compared to untreated controls (not shown). This lack of apoptotic response in 
free-cholesterol-treated VSMCs correlated with the absence of intracellular cholesterol 
vesicles, which were abundant in BMDMs exposed to this lipid (not shown).  
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DISCUSSION 
The major finding of the present study is that deficiency of the p19Arf protein, one of the tumor 
suppressors encoded by the CDKN2A gene, accelerates atheroma development in the 
atherosclerosis-prone aortic arch (en face study) and aortic root (analyzed in tissue cross-
sections) of hypercholesterolemic apoE-null mice (Fig.1). This phenotype is not observed in 
less atherogenic regions of the same mice (eg. ascending and thoracic aorta), suggesting that 
p19Arf is not involved in the initiation of atherosclerosis but regulates atheroma development in 
more advanced stages of the disease. Notably, apoptosis is reduced in apoE-/-p19-/- compared 
to apoE-/- plaques (Fig.4), and p19Arf inactivation attenuates apoptosis in primary cultures of 
macrophages and VSMCs exposed to different pro-apoptotic stimuli (Fig.5). Of note, recent 
genome-wide association studies in humans have reported an association between several 
SNPs in a region of chromosome 9p21 adjacent to the CDKN2A/CDKN2B loci and the risk of 
atherosclerotic diseases (19-25). Moreover, it has been shown that expression of transcripts 
encoded by these genes (eg. p15INK4b, p16INK4a, ANRIL, and p14ARF, the human homolog of 
murine p19Arf) is lower in purified peripheral blood T-cells of individuals homozygous for the 
atherosclerosis risk G-allele of one of these SNPs (rs10757278) (26). Thus, our findings 
demonstrating a direct link between p19Arf, plaque apoptosis and atherosclerosis burden in 
apoE-/- mice suggest a molecular mechanism by which diminished expression of ARF 
associated to genetic variants in the CDKN2A gene may increase the risk of atherosclerosis 
by limiting plaque apoptosis.   
Since p19Arf expression has been shown to promote cellular senescence to avoid 
proliferation of aberrant, potentially hazardous cells in some pathophysiological settings (e.g. 
aging and cancer) (10,11), we evaluated aortic cell senescence in apoE-/- (n=10) and apoE-/-
p19-/- (n=9) mice fed the atherogenic diet for 9 weeks. In both groups of mice, we found 
essentially negligible senescence-associated beta-galactosidase staining in cryosections 
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through the aortic valves, with some scarce faintly positive cells within the neighboring cardiac 
tissue (data not shown). Thus, reduced aortic cell senescence does not appear to contribute 
to increased atherosclerosis in apoE-/-p19-/- mice. We also investigated the consequences of 
disrupting p19Arf on the expression of the proto-oncogen Myc, since both proteins have been 
shown to directly interact and p14Arf down-regulates Myc activated transcription (32). qPCR 
analysis demonstrated increased c-myc expression in mouse aortic VSMCs lacking  p19Arf 
(Fig.S3A, on-line supplement), which, together with the lack of compensatory upregulation of 
p16INK4a, might contribute to the higher proliferative capacity of cultured apoE-/-p19-/- VSMCs 
(Fig.3B).  Similarly, p19Arf inactivation augmented significantly c-myc expression in aortic arch 
of apoE-/- mice fed the atherogenic diet for 4 weeks (Fig.S3B, on-line supplement), but this 
response did not correlate with changes in cell proliferation within the atheroma (Fig.S1, on-
line supplement). Moreover, c-myc expression was similar in apoE-/- and apoE-/-p19-/- mice fed 
atherogenic diet for 9 weeks (Fig.S3B, on-line supplement). Thus, the effect of p19Arf on c-myc 
expression in the aortic arch appears to depend on lesional stage (eg., increased expression 
in small lesions at 4 weeks of fat diet and no effect in more advanced lesions after 9 weeks of 
diet). Hence, further research appears warranted to elucidate the complex functional 
connections between c-myc, p19Arf and proliferation at different stages of atherosclerosis. 
Both cell proliferation and apoptosis are prevalent in atherosclerotic lesions (5-8). 
Therefore, changes in the balance between hyperplastic growth and apoptosis of neointimal 
cells are of major importance in atherosclerosis development. Indeed, atheroma progression 
is affected in mice with altered expression of several tumor suppressors which modulate cell 
proliferation and apoptosis. Unlike p21Cip1, whose genetic ablation unexpectedly protects from 
atherosclerosis in apoE-null mice (33,34), the absence of p53 (35-38), p27Kip1 (39,40), and 
retinoblastoma (41) proteins aggravates atherosclerosis in different murine models (apoE-null, 
LDL receptor-null, and apoE*3-Leiden transgenic mice). Excessive proliferation of 
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macrophages and VSMCs has been suggested as a mechanism contributing to the 
acceleration of atherosclerosis in mice lacking p27Kip1, retinoblastoma and p53. We also found 
increased atherosclerosis burden in apoE-null mice lacking p19Arf; however, this phenotype 
did not appear to correlate with increased cell proliferation within the plaque, possibly due to a 
marked upregulation in aortic tissue of the INK4-family growth suppressor p16INK4a (Fig.S2A). 
This compensatory mechanism does not appear to occur in cultured VSMCs since apoE-/-p19-
/- VSMCs exhibited increased proliferative capacity compared with apoE-/- controls and no 
statistically-significant differences in p16INK4a expression were detected between cells of both 
genotypes (Fig.S2B).  
In agreement with the well-established pro-apoptotic function of p19Arf, our in vivo studies 
reveal a two-fold reduction in the content of apoptotic cells in apoE-/-p19-/- compared with 
apoE-/- plaques (Fig.4A). Notably, we find that the relative proportion of apoptotic neointimal 
macrophages and VSMCs is unchanged in apoE-/-p19-/- and apoE-/- mice (70% and <4%, 
respectively) (Fig.4B), suggesting that lack of p19Arf protects from apoptosis to the same 
extent in both cell types. Future studies are required to investigate whether apoptosis of other 
cell types present in the atheroma might be differentially affected by p19Arf ablation. 
Consistent with our in vivo results, p19Arf inactivation also reduces apoptosis by 30-57% in 
BMDMs and VSMCs cultures exposed to different proapoptotic stimuli (Fig.5). The finding that 
GSNO-induced apoptosis is attenuated in apoE-/-p19-/- cells is in concordance with previous 
studies demonstrating that efficient nitric oxide-dependent macrophage apoptosis requires the 
activation of p19Arf (42).  
Consistent with the possibility that decreased apoptosis is a mechanism by which p19Arf 
inactivation aggravates atheroma progression, a reduction in apoptotic cell death, 
accompanied or not by changes in cellular plaque proliferation, has been previously 
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associated with increased atherosclerosis in several genetically-modified mouse models. For 
example, ablation of p53, a downstream target of p19Arf, reduces apoptosis and increases 
atheroma formation in some of the models studied (37,38). Moreover, the unexpected 
aggravation of atherosclerosis in apoE-/- compared to apoE-/-p21-/- mice also coincides with 
reduced neointimal apoptosis (33), in agreement with the reported anti-apoptotic role of 
p21Cip1 (43). However, decreased macrophage apoptosis might be beneficial in advanced 
stages of atherosclerosis by reducing the risk of plaque rupture (44). 
Conclusions. Genetic inactivation of p19Arf in atherosclerosis-prone apoE-null mice limits 
apoptosis of neointimal macrophages and VSMCs and worsens atherosclerosis without 
affecting neointimal cell proliferation, possibly due to a compensatory upregulation of p16INK4a. 
These findings suggest that interventions aimed at increasing the expression of ARF may 
lessen plaque progression. Our results also support the notion that decreased plaque 
apoptosis might contribute to increased risk of atherosclerosis in individuals homozygous for 
the G-allele of rs10757278, who exhibit reduced levels of not only ARF, but also p15INK4b, 
p16INK4a, and ANRIL transcripts in blood-borne T-cells (26). Thus, it will be of interest to 
generate additional mouse models to determine whether atherosclerosis is also aggravated 
upon deficiency of p15INK4b, p16INK4a, and ANRIL, and if combined inactivation of two or more 
CDKN2A/CDKN2B genes potentiates atherosclerosis more than does single gene ablation. 
Moreover, further studies are warranted to ascertain if other atherosclerosis risk variants near 
the CDKN2A/CDKN2B loci also lead to diminished expression of INK4/ARF transcripts. 
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Figure Legends 
 
Figure 1. p19Arf inactivation aggravates diet-induced atherosclerosis in apoE-/- 
mice. (A) Body weight at beginning of the diet (0 weeks) and at different time points of 
fat feeding. Comparisons vs. same genotype: #, p<0.0001 vs. wk 0; # #, p<0.05 vs. wk 
0; †, p<0.005 vs. wk 1; ††, p<0.0005 vs. wk 1; *, p<0.0007 vs. wk 4. (B) Fasting 
plasma total cholesterol (Total-C), HDL cholesterol (HDL-C) and triglycerides (TAG) 
before and after 9 weeks of fat feeding. Comparisons vs. prediet same genotype: #, 
p<0.0001; # #, p<0.0008. (C) Atherosclerosis burden measured in Oil Red O-stained 
aorta. (D) Atherosclerosis burden determined as lesional area (mm2) in cross-sections 
of the aortic root and ascending aorta (for each mouse average of three cross-sections 
separated by approximately 9 μm). For statistical analysis, two-way ANOVA was used 
in panels A and B and Student’s t-test in panels C and D. 
Figure 2. p19Arf inactivation in fat-fed apoE-null mice does not affect 
atherosclerotic plaque composition. Cross-sections from the aortic root (A) and 
from the ascending aorta (B) were stained with anti-Mac3, anti-SM α-actin and 
Masson´s trichrome to quantify the neointimal content of macrophages, VSMCs and 
collagen, respectively. Quantification is shown as percentage of stained area relative 
to the area occupied by atheroma. The photomicrographs (50x magnification) show 
representative images of aortic root sections. Differences between groups were 
evaluated by Student’s t-test 
 
Figure 3. Effects of p19Arf inactivation on cell proliferation in lesions and in 
cultured macrophages and VSMCs. Statistical analysis was carried out using 
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Student’s t-test in panel A and C and two-way ANOVA in panel B. (A) Proliferating 
BMDMs were detected by immunofluorescence to visualize BrdU incorporation using 
anti-BrdU antibody. Results are shown as a percentage of BrdU positive vs. total cells 
and are the average of four independent experiments (three pools of BMDM per 
experiment per genotype). Representative images are shown at 200X magnification. 
(B) VSMC cell cycle profile analysis by flow cytometry. Cells were synchronized at 
G0/G1-phase by serum deprivation for 72h and restimulated for the indicated times. 
The results are representative of two independent experiments. For simplicity, only 
statistical comparisons between apoE-/- and apoE-/-p19-/- VSMCs at each time point of 
serum restimulation are shown.  In apoE-/- cultures, differences in the %  of cells in 
G1/G0-, S- and G2/M-phases only reached statistical significance after 24h of serum 
restimulation compared to 0h (p<0.0001). However, in apoE-/-p19-/- VSMCs, 
differences in G1/G0-, S- and G2/M-phases reached statistical significance at 8, 16 
and 24h after serum restimulation compared to 0h (8h vs 0h and 16h vs. 0h: p<0.05; 
24h vs. 0h: p<0.0001). (C) Aortic root cross-sections from mice fed atherogenic diet for 
9 weeks were stained with anti-Ki67 antibody to quantify cell proliferation. Images were 
captured at a magnification of 1000X and quantification is shown as percentage of 
positive cells within the neointimal lesion.  
 
Figure 4. p19Arf inactivation in apoE-/- mice reduces apoptosis in atherosclerotic 
lesions. Aortic root cross-sections from fat-fed mice were analyzed. (A) Apoptosis 
quantified as percentage of TUNEL-positive cells within the lesion and as TUNEL-
positive cells per mm2 of lesion. (B) Sections were doubly stained with TUNEL/Mac3 
(top) or TUNEL/SM α-actin (bottom) to identify apoptotic macrophages and VSMCs, 
respectively. The results are represented as % of cells doubly positive for TUNEL and 
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Mac3 or SM α-actin relative to the total number of TUNEL-positive cells within the 
atheroma. The  photomicrographs show representative images at a magnification of 
1000X. Statistical analysis was carried out using the Mann-Whitney U-test. 
 
Figure 5. p19Arf inactivation reduces apoptosis in primary  BMDM and VSMC 
cultures. Apoptotic cells were identified by flow cytometry as the sub-G0 population 
after propidium iodide staining or as cleaved-caspase-3-immunoreactive cells. Results 
using both methods represent the average of two independent experiments each 
performed in triplicate. Representative plots are shown below the graphs. (A) BMDMs 
were untreated (basal), irradiated with UV light (80 J/m2 and harvested after 24h), or 
incubated with 2 mM GSNO (2mM) or free-cholesterol (FC, 100g/ml) for 24h. Results 
represent the average of three independent experiments (apoE-/-: three pools of cells 
per experiment; apoE-/-p19-/-: four pools of cells per experiment) (B) VSMCs were 
untreated (basal), irradiated with UV light (120 J/m2 and harvested after 48h), or 
incubated with 2 mM GSNO for 48h. Statistical analysis was carried out using two-way 
ANOVA. 
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